Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + tetanus toxoid + acellular pertussis + inactivated poliovirus + haemophilus b conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A combination vaccine containing five antigens: **diphtheria toxoid**, **tetanus toxoid**, **acellular pertussis antigens** (usually including pertussis toxoid, filamentous hemagglutinin, pertactin, fimbriae 2 and 3), **inactivated poliovirus serotypes 1, 2, and 3**, and **Haemophilus influenzae type b (Hib) polysaccharide conjugated to tetanus toxoid (PRP-T)**. The vaccine induces protective immunity by generating antibody responses to each included antigen, thereby preventing diphtheria, tetanus, pertussis, poliomyelitis, and invasive Haemophilus influenzae type b disease in infants and young children. It is administered intramuscularly in children from 6 weeks up to 4 years of age, prior to the fifth birthday[1][3][5][9].
- Brand names
- Pentacel
- Other names
- DTaP-IPV/HibDTaP-IPV-Hibdiphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and Haemophilus b conjugate vaccine
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on diphtheria toxoid + tetanus toxoid + acellular pertussis + inactivated poliovirus + haemophilus b conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + acellular pertussis + inactivated poliovirus + haemophilus b conjugate vaccine.